THE RESULTS OF THE APPLICATION OF HISTOCHROME IN THE CHILDREN PRESENTING WITH ACTIVE RETINOPATHY OF PREMATURITY


Cite item

Full Text

Abstract

This paper is designed to report the results of the application of histochrome for the treatment of the children presenting with «pre-plus» disease and concomitant active retinopathy of prematurity. The preparation was administered intramuscularly in the form of a 0.02% solution. The effectiveness criteria included the time between the onset of the disease and the development of its threshold stage, the area of avascular retina by the time of emergence of the threshold stage, and the frequency of spontaneous regression and beneficial outcomes of retinopathy of prematurity. The results of histochrome injections given to 25 children (50 eyes) were compared with those obtained in the control group comprised of 16 children (32 eyes). The patients of both groups were matched not only for somatic parameters but also for the severity of clinical symptoms of retinopathy of prematurity. It was shown that histochrome injections to the children exhibiting large areas of avascular retina at the stages of pre-retinopathy, pre-threshold plus-disease, and pre-plus disease (1) increased the frequency of spontaneous regression of the pathological process (to 44.0% compared with 12.5% in controls) and (2) slowed down its development into the threshold stage (the period from the onset of manifestations of retinopathy of prematurity to the threshold stage was as long as 0.7-9 (mean 4.11 ± 0.57) weeks compared with 0.6-3.5 (mean 2.28 ± 0.19) weeks in controls. Taken together, these changes promoted the reduction of the area of avascular retina by the time of laser coagulation. As a result, the cicatrical changes in the subsequent period were less pronounced. Moreover it allowed to postpone the surgical intervention till the child becomes older and therefore is at a lower risk due to the less aggravated somatic condition. (3) Finally the effectiveness of laser coagulation was enhanced.

About the authors

E. N Demchenko

Helmholtz Moscow Research Institute of Eye Diseases

канд. мед. наук, мл. науч. сотр. отд. патологии глаз у детей

I. A Belyaeva

Research Centre of Children’s Health, Russian Academy of Medical Sciences

д-р мед. наук, рук. отд. для недоношенных детей

L. A Katargina

Helmholtz Moscow Research Institute of Eye Diseases

д-р мед. наук, проф., рук. отд. патологии глаз у детей, зам. дир. ин-та по науч. работе

References

  1. Бесланеева М. Б. Антиоксидантная терапия внутриглазных кровоизлияний при травмах глаз у детей: Автореф. дис.. канд. мед. наук. - М., 2009.
  2. Гусева М. Р., Дубовская Л. А., Чиненов И. М. и др. Комплексное лечение внутриглазных кровоизлияний с применением антиоксидантного препарата гистохром у детей // Рефракц. хир. и офтальмол. - 2003. - Т. 3, № 1. - С. 70-76.
  3. Гусева М. Р., Бесланеева М. Б., Мищенко Н. П., Хурай А. Р. Особенности проникновения антиоксидантного препарата гистохром через гематоофтальмический барьер (экспериментальное исследование) // Вестн. офтальмол. - 2007. -№ 6. - С. 38-40.
  4. Еляков Г. Б., Максимов О. Б., Мищенко Н. П. и др. Препарат гистохром для лечения воспалительных заболеваний сетчатки и роговицы глаз. Пат. РФ 2134107 // Бюл. изобрет. -1999. - № 22. - С. 280.
  5. Катаргина Л. А., Коголева Л. В. Ретинопатия недоношенных // Избранные лекции по детской офтальмологии / Под ред. В. В. Нероева. - М., 2009. - С. 27-61.
  6. Мищенко Н. П., Федореев С. А., Догадова Л. П. Препарат гистохром для офтальмологии // Вестн. ДВО РАН. - 2004. -№ 3. - С. 111-119.
  7. Николаева Г. В., Гусева М. Р., Бесланеева М. Б. Применение антиоксидантов для профилактики и лечения ретинопатии недоношенных // Сборник трудов науч.-практ. конф. Российского общенационального офтальмологического форума. -М., 2012. - С. 637-640.
  8. An International Committee for the Classification of Retinopathy of Prematurity. The international classification of ROP - revisited // Arch. Ophthalmol. - 2005. - Vol. 123. -P 991-999.

Copyright (c) 2013 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies